<DOC>
	<DOCNO>NCT00000612</DOCNO>
	<brief_summary>To conduct three-armed trial assess effect soy phytoestrogens menopausal complaint , plasma lipid lipoprotein , vaginal bleed endometrial proliferation , health relate quality life .</brief_summary>
	<brief_title>Soy Estrogen Alternative Study ( SEA )</brief_title>
	<detailed_description>BACKGROUND : The result many study indicate estrogen replacement therapy ( ERT ) reduce risk coronary heart disease ( CHD ) postmenopausal woman . However , less 9 percent woman choose take ERT unwanted side effect concern increase risk cancer associate ERT . Therefore , alternative therapy need . The isoflavonoids find soy protein ( specifically genistein ) many property may reduce risk coronary heart disease . These include favorable effect plasma lipid coronary artery vasomotion . Furthermore , genistein tyrosine kinase ( TK ) inhibitor inhibitory effect thrombin activity TK receptor-linked mitogen may associate atherogenesis neointimal formation angioplasty . DESIGN NARRATIVE : Randomized , double-blind , placebo-controlled . The woman randomize one three group : placebo , conjugate equine estrogen , soy supplementation . Primary endpoint impact menopausal complaint hot flush , mood lability , anxiety , sleep disturbance ; effect plasma lipid lipoprotein , include lipoprotein ( ) ; effect vaginal bleed endometrial proliferation ; change health-related quality life . Secondary endpoint include : assessment impact intervention progression carotid artery intimal medial wall thicken assess B-mode ultrasonography ; bone density bone turnover ; additional measure monitor compliance safety intervention mammography , anticipate known side effect hormone replacement therapy , blood level genistein , clinical outcome hospitalization , physician visit , symptom . The study end December , 1998 . The study subproject within program project coronary atherosclerosis female , primarily monkey . Dr. Thomas B. Clarkson P.I . The subproject dollar estimate base CRISP dollar assign study approximately 12 percent total program project dollar broken follow : FY 1996 - 219,254 ; FY 1997 - $ 217,000 ; FY 1998 - $ 221,000 . The study completion date list record obtain `` End Date '' enter Protocol Registration Results System ( PRS ) record .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Uterine Diseases</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Perimenopausal/menopausal woman , age 45 55 .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2000</verification_date>
</DOC>